Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DAPD (Emory University/Triangle Pharmaceuticals/Abbott Laboratories).

A H Corbett1, J C Rublein

  • 1The University of North Carolina Hospitals, Department of Pharmacy, Chapel Hill 27514, USA. AHCorbet@unch.unc.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|September 29, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.

HIV medicine·2013
Same author

Mms22p protects Saccharomyces cerevisiae from DNA damage induced by topoisomerase II.

Nucleic acids research·2005
Same author

Nuclear transport mechanisms.

Cellular and molecular life sciences : CMLS·2002
Same author

Functional analysis of the yeast Ran exchange factor Prp20p: in vivo evidence for the RanGTP gradient model.

Molecular genetics and genomics : MGG·2001
Same author

Conditional mutations in gamma-tubulin reveal its involvement in chromosome segregation and cytokinesis.

Molecular biology of the cell·2001
Same author

Interaction between Ran and Mog1 is required for efficient nuclear protein import.

The Journal of biological chemistry·2001
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Triangle Pharmaceuticals is developing dioxolane guanosine (DAPD), a novel antiviral agent, for HIV and HBV infections. Clinical trials are underway, and DAPD shows promise as a unique therapeutic option.

Area of Science:

  • Antiviral drug development
  • Nucleoside analog research
  • Virology

Background:

  • DAPD is a prodrug of dioxolane guanosine, a viral replication inhibitor.
  • It is being developed by Triangle Pharmaceuticals for HIV and HBV infections.
  • DAPD represents a distinct nucleoside series with potential advantages over existing therapies.

Purpose of the Study:

  • To evaluate DAPD as a potential therapy for Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) infections.
  • To assess the safety and efficacy of DAPD through Phase I/II and Phase II clinical trials.

Main Methods:

  • Phase I/II dose-ranging studies for HIV treatment.
  • Planned clinical development for HBV infection.
  • Ongoing Phase II trials scheduled for Q2 2001.

Related Experiment Videos

Main Results:

  • DAPD has received Fast Track designation from the FDA.
  • Preclinical data suggest efficacy in combination therapies for both treatment-naive and treatment-experienced HIV patients.
  • Potential utility against drug-resistant HIV-1 strains.

Conclusions:

  • DAPD is a promising antiviral candidate with potential advantages due to its unique structure.
  • It is being developed in collaboration with Abbott Laboratories.
  • Further clinical evaluation is warranted for HIV and HBV treatment.